
Dr Reddy's halts semaglutide supply over quality concerns
The story in brief
Dr Reddy's Laboratories faced supply issues with its semaglutide injection, Obeda, after certain batches were found out of specification. The company is investigating the cause and ensuring product quality, though it did not specify when the issues would resolve. Semaglutide is a key ingredient in Novo Nordisk's diabetes and obesity drugs, and over half a dozen Indian firms have launched cheaper alternatives.